Mark J. Foley
2020
In 2020, Mark J. Foley earned a total compensation of $8.8M as President and CEO at Revance Therapeutics, a 49% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $328,331 |
|---|---|
| Salary | $650,000 |
| Stock Awards | $7,794,350 |
| Other | $8,255 |
| Total | $8,780,936 |
Foley received $7.8M in stock awards, accounting for 89% of the total pay in 2020.
Foley also received $328.3K in non-equity incentive plan, $650K in salary and $8.3K in other compensation.
Rankings
In 2020, Mark J. Foley's compensation ranked 1,025th out of 13,090 executives tracked by ExecPay. In other words, Foley earned more than 92.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,025 out of 13,090 | 92nd |
Division Manufacturing | 361 out of 5,621 | 94th |
Major group Chemicals And Allied Products | 125 out of 2,254 | 95th |
Industry group Drugs | 110 out of 1,954 | 94th |
Industry Pharmaceutical Preparations | 80 out of 1,459 | 95th |
Pay ratio
| Mark J. Foley's Pay | $8,780,936 |
|---|---|
| Median Employee's Pay | $254,090 |
| Pay Ratio | 35to 1 |
In 2020, the annual total compensation of Mark J. Foley was $8,780,936.
The annual total compensation of the median employee at Revance Therapeutics was $254,090.
The ratio of Mark J. Foley's pay to the pay of median employee was therefore 35 to one.
Source: SEC filing on March 24, 2021.
Foley's colleagues
We found four more compensation records of executives who worked with Mark J. Foley at Revance Therapeutics in 2020.